This STAT Plus report investigates the evolution of the telehealth industry from a platform for increasing healthcare access to a primary vehicle for direct-to-consumer drug sales. It highlights how companies like Hims and Ro initially disrupted the market with erectile dysfunction treatments and are now capitalizing on the high demand for weight loss peptides. The article argues that this shift represents a broader consumerization of medicine, where virtual care serves as a marketing funnel for pharmaceutical products.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.